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Constitutive Activation of Stat3 Signaling
Confers Resistance to Apoptosis
in Human U266 Myeloma Cells
progression of MM by regulating the growth and survival
of myeloma tumor cells (Kawano et al., 1988; Klein et
al., 1995). IL-6 induces intracellular signaling through
members of the signal transducers and activators of
transcription (STAT) family of proteins by mechanisms
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Figure 1. Activation of STAT Proteins in Bone Marrow Cells of Patients with Multiple Myeloma
(a) Nuclear extracts prepared from bone marrow cells were incubated with the 32P-labeled SIE oligonucleotide probe and analyzed by EMSA.
The mononuclear fraction was isolated from bone marrow aspirates from normal marrow donors (N), patients with no evidence of bone
metastases (Non-Hodgkin's lymphoma [NHL] or breast cancer [BrCa]), and patients with multiple myeloma (MM).
(b) Identification of specific STAT proteins activated in MM specimens. Untreated control extracts (lanes 1, 4, 7, 10, 13, 16, and 19), extracts
preincubated with anti-Stat1 (lanes 2, 5, 8, 11, 14, 17, and 20), or anti-Stat3 (lanes 3, 6, 9, 12, 15, 18, and 21) antibodies were incubated with
the 32P-labeled SIE probe and analyzed by EMSA. Positions of Stat3 homodimers (ST3/3), Stat1:Stat3 heterodimers (ST1/3), and Stat1
homodimers (ST1/1) are indicated.
expression of Bcl-xL in murine myeloma cells (Schwarze Results
and Hawley, 1995), the signaling pathways involved have
not been fully defined. High Frequency of STAT Activation
in Human MM TumorsBecause myeloma tumor cells are dependent on IL-6
for growth and survival, we assessed whether Stat3 may To examine the prevalence of STAT activation in primary
myeloma tumors, we evaluated STAT activity in thehave a role in the malignant progression of MM. In this
study, we demonstrate a high frequency of Stat3 activa- mononuclear fraction of bone marrow specimens ob-
tained from patients with MM. STAT activation can betion in bone marrow mononuclear cells from patients
with MM, whereas control bone marrows exhibit little detected by elevated DNA-binding activity as measured
in electrophoretic mobility shift assays (EMSA) using anor no detectable activated STATs. Furthermore, we
show that the human myeloma cell line U266, which is oligonucleotide probe corresponding to the sis-induc-
ible element (SIE), which binds activated Stat1 and Stat3dependent on an IL-6 autocrine loop, harbors constitu-
tively activated Stat3 and expresses high levels of Bcl-xL (Yu et al., 1995). Nuclear extracts prepared from bone
marrow specimens reveal elevated SIE-binding activity,protein as compared to the IL-6-independent myeloma
cell line, RPMI 8226. Using specific inhibitors of the to varying extents, in all 24 MM patients examined, with
dramatic elevation in one-third of these (Figure 1a). InIL-6 receptor, JAK family kinases and Stat3 protein, we
delineate an IL-6 signaling pathway from JAKs through contrast, little or no activated STATs were detected in
bone marrows from normal individuals or patients withStat3 to the bcl-x gene promoter in myeloma cells. Con-
sistent with the elevated levels of Bcl-xL, U266 cells are no evidence of bone marrow metastases. To identify
the STAT family members activated in MM tumor cells,resistant to Fas-mediated apoptosis despite high levels
of Fas receptor expression. Blocking activation of Stat3 supershift experiments were performed using antibod-
ies specific for different STATs. Stat3 homodimers andsignaling in U266 cells inhibits Bcl-xL expression and
induces apoptosis. These results indicate that the anti- Stat1:Stat3 heterodimers are the predominant forms of
activated STATs in the majority of MM specimens exam-apoptotic activity of IL-6 is mediated, at least in part,
through the activation of Stat3 in myeloma cells. Our ined (Figure 1b). Stat1 homodimer activation was pres-
ent at a lower frequency, and no Stat5 activation wasnovel findings provide evidence that elevated Stat3 sig-
naling directly contributes to the malignant progression detected using a Stat5-specific probe (data not shown).
These results demonstrate a high incidence of constitu-of MM by preventing apoptosis and thus conferring a
survival advantage. tively elevated Stat3 activation in MM tumor cells.
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Figure 2. Elevated STAT DNA-Binding Activity in Human Myeloma Cells Depends on Signaling by IL-6 Receptor and JAK Family Kinases
(a) Nuclear extracts prepared from U266 or RPMI 8226 cells were incubated with the 32P-labeled SIE oligonucleotide probe and analyzed by
EMSA. NIH 3T3 cells were stimulated with EGF as a reference for the identification of STAT proteins. Untreated extracts (lanes 1, 2, 3, 7, and
10); extracts preincubated with anti-Stat1 (lanes 4 and 11), anti-Stat3 (lanes 5 and 12), or anti-Stat5s (lane 6 and 13) antibodies to identify
activated STATs. Prior to analysis by EMSA, extracts were preincubated with excess unlabeled FIRE as an irrelevant oligonucleotide (lane 8)
or unlabeled SIE oligonucleotide (lane 9) as specific competitor.
(b) U266 cells were either untreated (lanes 1±3) or treated with 1 mg/ml Sant7 (lanes 4±6), and nuclear extracts were prepared at the times
indicated.
(c) Cells were treated with 50 mM AG490 for the times indicated prior to preparation of nuclear extracts.
Stat3 Activation in U266 Myeloma Cells Stat1:Stat3 heterodimers and Stat1 homodimers (Figure
2a). This pattern of STAT activation in U266 cells is thusIs Constitutive and Dependent on
Signaling from IL-6 Receptor similar to that of many MM tumor specimens described
above.to JAK Family Kinases
The human myeloma cell line U266 has a well-character- Further experiments were designed to define the sig-
naling pathways responsible for Stat3 activation in my-ized IL-6 autocrine loop and depends on its own produc-
tion of the cytokine for growth and survival (Schwab et eloma cells. Sant7 is a potent IL-6 superantagonist that
competes with IL-6 for binding to surface IL-6 receptorsal., 1991; Keller and Erschler, 1995). Nuclear extracts
prepared from U266 cells exhibit constitutive SIE-bind- and prevents the gp130 subunits from oligomerizing and
initiating downstream signaling (Sporeno et al., 1996).ing activity that is specifically competed by unlabeled
SIE but not by an irrelevant oligonucleotide (Figure Inhibition of IL-6 receptor signaling by Sant7 reduces
constitutive Stat3 DNA-binding by nearly 70% within 122a). Although U266 cells are dependent on an IL-6 auto-
crine loop, stimulation with exogenous IL-6 induces fur- hr and persists for at least 24 hr in U266 cells (Figure
2b). Complete abrogation of STAT activity by Sant7 wasther activation of STAT DNA-binding activity (data not
shown). By contrast, the IL-6-independent human my- not observed, possibly reflecting the contribution of an
intracellular IL-6 autocrine loop or signaling by othereloma cell line RPMI 8226, which harbors a Ras muta-
tion, is negative for STAT activation, consistent with cytokines that also activate STATs, neither of which
would be completely blocked by Sant7. Involvement ofactivation of other signaling pathways (Hallek et al.,
1998). To confirm the identity of STAT family members JAKs in Stat3 signaling was investigated by using a
specific inhibitor of JAK family kinases, the tyrphostinactivated in U266 cells, control experiments were per-
formed using nuclear extracts from EGF-stimulated NIH AG490 (Meydan et al., 1996). Constitutive Stat3 DNA-
binding activity is inhibited by AG490 in a time-depen-3T3 cells as a reference (Zhong et al., 1994) and antibod-
ies specific for different STAT family members. The SIE- dent manner, with complete abrogation of Stat3 activity
occurring within 16±24 hr in U266 cells (Figure 2c). To-binding activity in U266 cells contains predominantly
activated Stat3 homodimers and, to lesser extents, gether, these results demonstrate that the majority of
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Figure 3. U266 Myeloma Tumor Cells Ex-
press Fas Receptors but Are Resistant to
Fas-Mediated Apoptosis
(a) Surface expression of Fas (CD95) was
measured by staining with the nonapoptosis-
inducing antibody UB2 (solid line) or IgG1 iso-
type control (dotted line) and FITC-conju-
gated secondary MAb.
(b) Fas-mediated apoptosis was measured
by incubation of the cells with IgM control
serum (upper panels) or 500 ng/ml of the Fas
agonist antibody CH-11 (lower panels) for 18
hr prior to staining with Annexin V-FITC and
analysis by flow cytometry. Treatment with
100 ng/ml Fas ligand gave identical results
(data not shown). Histograms shown are rep-
resentative of five independent experiments.
(c) Constitutive expression of Bcl-2 and Bcl-
xL in 8226 and U266 human myeloma cells.
Total RNA was extracted and analyzed by
RT±PCR. Histone 3.3 served as a control for
quantitation and RNA integrity. Radiolabeled products were separated on a 3% acrylamide gel and visualized by phosphorimager. Bcl-xL (left
column) and Bcl-2 (right column) protein expression was examined by Western blot analysis with ECL detection.
constitutive Stat3 activation observed in U266 myeloma effect on the expression of Bcl-2 or the housekeeping
genes histone 3.3 and b-actin, demonstrating that AG490cells is mediated by IL-6 signaling from the IL-6 receptor
to JAK family kinases. treatment does not induce a general block in gene tran-
scription or translation.
We next examined if the inhibition of Bcl-xL expressionU266 Myeloma Cells Express Elevated Levels
of Bcl-xL and Are Inherently Resistant by AG490 increases sensitivity to Fas-mediated apopto-
sis. Following 24 hr of exposure to AG490, U266 cellsto Apoptosis
Comparison of the two model human myeloma cell lines were treated with the Fas agonistic MAb CH-11 for an
additional 12 hr and analyzed for programmed cellreveals a relative difference in resistance to Fas-medi-
ated apoptosis by the IL-6-dependent cell line U266 as death. Strikingly, following reduction in Bcl-xL expres-
sion, U266 cells display a marked increase in sensitivitycompared to 8226, which is not dependent on IL-6. Both
myeloma cell lines express high levels of Fas on their to Fas-mediated apoptosis (Figure 4b), with up to 90%
of cells undergoing apoptosis. This effect is not likelycell surface (Figure 3a). However, treatment of 8226 cells
with Fas ligand or the agonistic MAb CH-11 results in to be a general stress response, as AG490 treatment
does not enhance sensitivity to Fas-mediated cell death40%±65% apoptosis, whereas U266 cells are com-
pletely resistant to Fas-mediated cell death (Figure 3b). in the IL-6-independent 8226 cells (data not shown).
With extended exposure to AG490 for 48 hr, 70% of U266This resistance cannot be attributed to reduced receptor
expression, nor is it due to function-ablating mutations cells accumulate in G1 and at 72 hr display extensive
spontaneous cell death (data not shown). This obser-(Landowski et al., 1997) (data not shown). To address
the mechanism of Fas resistance in the U266 cell line, vation is compatible with previous reports that dem-
onstrated a G1 block and cell death in myeloma cellswe examined the expression of the antiapoptotic pro-
teins Bcl-2 and Bcl-xL. Constitutive mRNA and protein under conditions of IL-6 deprivation (Schwab et al.,
1991; Schwarze and Hawley, 1995). Combined with theexpression of both Bcl-2 and Bcl-xL are higher in U266
cells as compared to 8226 cells, with levels 2- to 7-fold data in Figure 2, these findings raise the possibility that
Stat3 signaling contributes to the resistance of U266greater after normalization (Figure 3c). This observa-
tion is in agreement with recent reports showing that cells to programmed cell death by inducing expression
of Bcl-xL. While AG490 is selective for JAK family kinasesBcl-xL overexpression protects hematopoietic cells from
Fas-mediated apoptosis (Boise and Thompson, 1997; (Meydan et al., 1996), we cannot exclude the possibility
that AG490 inhibits other tyrosine kinases in the IL-6Schneider et al., 1997).
signaling pathway that may contribute to regulation of
apoptosis.AG490 Inhibits Expression of Bcl-xL and Promotes
Apoptosis in U266 Cells
We disrupted IL-6 receptor signal transduction to exam- Dominant-Negative Stat3 Protein Inhibits Expression
of Bcl-xL and Promotes Apoptosis in Transfectedine the role of IL-6-mediated Bcl-xL expression in regu-
lating apoptosis of U266 cells. Inhibition of JAK family U266 Myeloma Cells
Because multiple signal transduction pathways havekinase activity by AG490 treatment results in a signifi-
cant reduction of bcl-x mRNA expression following 24 been shown to originate from the IL-6 receptor (Akira
et al., 1994; Ogata et al., 1997), we next examined thehr of exposure, and by 30 hr the Bcl-xL protein levels are
nearly absent (Figure 4a). The kinetics of Bcl-xL inhibition effects of a dominant-negative Stat3 protein on Bcl-xL
expression and cell survival. Stat3b is a naturally oc-closely follow the kinetics of Stat3 inhibition by AG490
(compare with Figure 2c). In contrast, AG490 has no curring splice variant of Stat3 that lacks the C-terminal
Stat3 Signaling in Multiple Myeloma
109
empty vector transfectants and analyzed by RT±PCR.
Results demonstrate a reduction in bcl-x mRNA levels,
similar to the reduction in Bcl-xL protein, in Stat3b-
expressing cells (Figure 5a). In contrast, Bcl-2 protein
and mRNA levels were not substantially reduced in
Stat3b-expressing cells, consistent with the AG490 re-
sults described above.
Significantly, when we examined transiently trans-
fected Stat3b-expressing U266 cells by Annexin V-PE
staining and FACS analysis, a high level of apoptosis
was observed relative to empty vector transfectants. At
72 hr posttransfection, 66% of Stat3b-expressing cells
were apoptotic, compared to only 28% of cells trans-
fected with empty vector (Figure 5b). There was only a
modest increase in apoptosis of Stat3b-expressing cells
in response to the Fas agonistic antibody CH-11, proba-
bly due to the high levels of spontaneous apoptosis
already in progress in Stat3b-expressing cells. These
conclusions were confirmed by fluorescence and light
microscopy of Stat3b-expressing cells enriched by FACS
sorting on the basis of EGFP expression. Following stain-
ing with DAPI for morphological examination, fluores-
cence microscopy was used to identify green fluores-
cent cells expressing Stat3b. Results show that the
majority of cells expressing Stat3b exhibit nuclear frag-
mentation characteristic of apoptosis, whereas cells not
expressing Stat3b are normal in appearance (Figure 6).
Figure 4. AG490 Inhibits Bcl-xL Expression and Sensitizes U266 These results demonstrate that Stat3-dependent signal-Cells to Fas-Mediated Apoptosis
ing is critical for the survival of myeloma tumor cells
(a) U266 cells were treated with 50 mM AG490 for the indicated time
and their resistance to programmed cell death, consis-and analyzed for expression of Bcl-xL (left column) and Bcl-2 (right
tent with the finding that Stat3 activation by gp130-column) mRNA and protein. To control for potential variation related
to time, untreated controls were collected at all time points and mediated signaling is required for preventing apoptosis
identically analyzed. Data shown are representative of three inde- in murine pro-B cells (Fukada et al., 1996).
pendent experiments.
(b) Fas-mediated apoptosis in AG490-treated cells. U266 were Stat3 Regulates Transcription from the bcl-x
treated with the indicated concentration of AG490 for 24 hr prior to
Gene Promoterthe addition of the agonistic anti-Fas antibody CH-11. Following an
Because the above results suggest that Stat3-mediatedadditional 12 hr of incubation, cells were stained with Annexin
V-FITC and analyzed for apoptosis by flow cytometry. Marker posi- signaling regulates Bcl-xL expression, we next investi-
tioning is based on fluorescence of control treatments, and data gated transcriptional regulation of the bcl-x promoter by
shown are representative of seven independent experiments in Stat3. For this purpose, we used mouse bcl-x promoter
which Fas-specific apoptosis ranged from 18% to 41%. constructs (Grillot et al., 1997) fused to a luciferase re-
porter gene (Figure 7a). Previous studies demonstrated
transactivation domain and functions in a dominant- that selective activation of Stat3 by the v-Src oncopro-
negative manner to block Stat3-mediated gene regula- tein induces Stat3-mediated gene expression in tran-
tion in many but not all cell types (Caldenhoven et al., siently transfected NIH 3T3 cells (Bromberg et al., 1998;
1996; Schaefer et al., 1997; Turkson et al., 1998). U266 Turkson et al., 1998). As shown in Figure 7b, activation
cells were transiently transfected with an enhanced of endogenous Stat3 by v-Src induces the expression
green fluorescent protein (EGFP) expression construct of bcl-x reporters 5- to 20-fold over basal levels in trans-
encoding Stat3b (pIRES-Stat3b) or the empty vector fected NIH 3T3 cells. This induction is Stat3-specific
(pIRES-EGFP). This construct contains an internal ribo- because it is effectively disrupted by overexpression of
somal entry site, allowing translation of Stat3b and EGFP Stat3b. Further analyses using serial upstream trunca-
from a single bicistronic mRNA. Because of the low tions of the bcl-x gene reveal that the 600 bp promoter-
transfection efficiency of human myeloma cells, Stat3b- proximal region contained in pGL2±0.6R is sufficient for
expressing cells were isolated by FACS on the basis of Stat3-mediated induction in response to v-Src (Figure
EGFP expression and then analyzed for Bcl-xL levels 7b). In addition, mutation of the reported Stat1-binding
48 hr posttransfection. Western blot analyses of FACS- site in this region of the bcl-x promoter (Fujio et al.,
sorted Stat3b-expressing cells reveal decreased Bcl-xL 1997) does not diminish transcriptional induction by
expression relative to empty vector transfectants (Figure v-Src (Figure 7b). Because v-Src induces exclusively
5a). Based on normalization to b-actin protein levels Stat3 and not Stat1 or other STAT family members in
probed on the same blot, results indicate that Bcl-xL NIH 3T3 cells (Yu et al., 1995; Cao et al., 1996; Garcia
protein levels are decreased by nearly 80% in the Stat3b- et al., 1997; Turkson et al., 1998), these results demon-
expressing cells. In separate experiments, mRNA was strate that Stat3 alone can mediate induction of the bcl-x
promoter.extracted from FACS-sorted Stat3b-expressing cells or
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Figure 5. Dominant-Negative Stat3b Protein
Inhibits Bcl-xL Expression and Enhances Pro-
grammed Cell Death
(a) U266 cells transfected with pIRES-Stat3b
or pIRES-EGFP were sorted on the basis of
EGFP expression and then analyzed for bcl-x
or bcl-2 mRNA and Bcl-xL or Bcl-2 protein
expression.
(b) U266 cells were transfected with pIRES-
EGFP or pIRES-Stat3b 48 hr prior to treat-
ment with IgM control serum (upper panels)
or 500 ng/ml CH-11 antibody (lower panels).
At 72 hr posttransfection, apoptotic cells
were stained with Annexin V-PE and analyzed
by flow cytometry with live gating on EGFP-
expressing cells. Marker positioning was
based on fluorescence of control treatments.
Treatment with 100 ng/ml Fas ligand gave
identical results (data not shown). The data
shown are representative of five independent
experiments.
Consistent with the observations in fibroblasts, trans- incidence of elevated Stat3 activation in MM tumor
specimens is in agreement with a recent study that re-fection of U266 myeloma cells with the bcl-x promoter
constructs results in greater than 25-fold increases in ported frequent elevated bcl-x expression in these tu-
mors (Tu et al., 1998). While it is likely that multipleexpression of these reporters relative to control pro-
moter in the inverse orientation (Figure 7c). Furthermore, cellular mechanisms contribute to the survival of MM
cells (Chauhan et al., 1997; Xu et al., 1998), results pre-transfected U266 cells respond to exogenous IL-6 stim-
ulation with an additional induction of the bcl-x promoter sented here demonstrate an essential role for Stat3 sig-
naling in preventing apoptosis of myeloma tumor cells.above the constitutive levels. Both the constitutive and
IL-6 induced activation of the bcl-x reporters is depen- The presence of APRE sequences and the response to
IL-6-induced Stat3 activation define bcl-x as a classicaldent on endogenous Stat3, as demonstrated by the abil-
ity of overexpressed Stat3b to block this induction in a acute-phase response gene (Wegenka et al., 1993). Pro-
tection from programmed cell death may be a featuredominant-negative manner. As in fibroblasts, the 600
bp bcl-x promoter-proximal region is sufficient to confer in common between the IL-6-induced acute-phase re-
sponse and malignant progression of MM tumors. Ourconstitutive and IL-6-induced expression in myeloma
cells, and the Stat1-binding site mutant pGL2-mST1 findings are consistent with an earlier report that the IL-
6-related cytokine LIF, which also signals through gp130shows an increase in expression relative to pGL2±0.6R
(Figure 7c). These results are consistent with our finding subunits, induces Stat1-mediated activation of the bcl-x
promoter and exhibits a cytoprotective effect in cardiacthat this highly conserved 600 bp region of the mouse
and human bcl-x genes harbors multiple Stat3-binding myocytes (Fujio et al., 1997). Because IL-6 induces
Stat1, albeit to a lesser extent than Stat3, we cannotsites, also called acute-phase response elements or
APRE sequences (Wegenka et al., 1993; Seidel et al., exclude the possibility that Stat1 also contributes to
induction of the bcl-x promoter in myeloma cells. Inter-1995).
estingly, however, mutation of the only known Stat1-
binding site increased expression of the bcl-x promoterDiscussion
in U266 myeloma cells (Figure 7c). EMSA analyses using
oligonucleotides corresponding to putative APRE se-Our findings delineate a complete signaling pathway
from IL-6 through Stat3 to the bcl-x gene (Figure 7d) quences in the 600 bp promoter region revealed the
presence of five Stat3-binding sites that do not bindand demonstrate that Stat3 signaling confers resistance
to apoptosis in human myeloma tumor cells. These novel Stat1, three of which are conserved between mouse and
human (R. C.-F. and R. J., unpublished data). While theseresults provide evidence that constitutively activated
Stat3 signaling contributes to the malignant progression findings suggest that Stat3 regulates the bcl-x promoter,
mutagenesis and footprinting experiments will be re-of MM by preventing apoptosis, thus allowing accumula-
tion of long-lived myeloma tumor cells. Because it is quired to confirm that Stat3 directly regulates transcrip-
tion by binding to the bcl-x promoter. Thus, stimulationwell established that Bcl-xL suppresses apoptotic death
of hematopoietic cells (Boise et al., 1993; Schwarze and of Stat1 and Stat3 signaling through IL-6-related cyto-
kines may confer cytoprotective effects through a com-Hawley, 1995; Silva et al., 1996; Boise and Thompson,
1997; Schneider et al., 1997), protection from apoptosis mon mechanism involving distinct STAT-binding sites
in the bcl-x promoter. In contrast to transient cytopro-in myeloma cells may be mediated, at least in part, by
Stat3-induced expression of Bcl-xL. This conclusion is tective effects that the acute-phase response confers
in normal cells, however, protection from cell death issupported by our observations that blocking Stat3 sig-
naling inhibits Bcl-xL expression and induces apoptosis chronic in tumor cells with constitutive Stat3 activation.
This distinction is likely to be critical in the recruitmentof myeloma cells. Moreover, our demonstration of a high
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Figure 6. Stat3b-Expressing Myeloma Cells Exhibit Characteristic Apoptotic Morphology
U266 cells were transfected with (a) pIRES-Stat3b or (b) pIRES-EGFP and sorted by FACS on the basis of EGFP expression. After sorting,
cells were recovered in complete media and applied to slides by cytospin, followed by methanol fixation for 20 min at 48C. Cells were stained
with DAPI and the slides examined by fluorescent microscopy.
of this normally cytoprotective pathway to a participa- expression of any one of these proteins can result in an
imbalance that affects the cellular response to physio-tory role in oncogenesis. Identification of bcl-x as one
physiologically relevant target gene for Stat3 with a logical signals for apoptosis. Fas is a key physiological
regulator of homeostasis in the immune system, whereknown function of biological consequence represents
an important first step in defining the role of Stat3 signal- it functions to delete activated effectors of the immune
response (Nagata and Golstein, 1995). We demonstrateing in normal cellular processes as well as oncogenesis.
The antiapoptotic activity of Bcl-xL has been attributed that Stat3 signaling regulates Bcl-xL expression and that
blocking Stat3 signaling leads to enhanced susceptibil-to its ability to form heterodimers and inactivate pro-
apoptotic members of the Bcl-2 family, including Bad, ity to Fas-mediated apoptosis and, ultimately, sponta-
neous programmed cell death. This is likely due, at leastBax, and Bak (Kelekar et al., 1997). Thus, dysregulated
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Figure 7. Stat3-Dependent Transactivation of the bcl-x Gene Promoter
(a) Structures of bcl-x promoter constructs driving expression of the luciferase (Luc) reporter gene. The pGL2±3.2-io construct contains the
bcl-x promoter sequences in the inverse orientation; the pGL-mST1 construct contains the mutated Stat1-binding site.
(b) Reporter constructs were cotransfected into NIH 3T3 fibroblasts together with expression vectors encoding v-Src or Stat3b as indicated.
The mean fold activation from three independent experiments, each performed in at least triplicate, is shown with standard error bars.
(c) Reporter constructs were cotransfected into U266 myeloma cells with the indicated expression vectors. The pIRES-EGFP construct is the
empty vector used to overexpress Stat3b, and rhIL-6 is recombinant human IL-6. Results represent the means plus standard deviations from
three independent transfections, each performed in at least triplicate.
(d) Model for IL-6 signaling through Stat3 to the bcl-x gene.
in part, to the relative increase in proapoptotic protein Tu et al., 1998). Because disruption of Stat3 signaling
reduces Bcl-xL expression and increases sensitivity toactivity resulting from the reduced Bcl-xL expression.
Although aberrant expression of Bcl-2 family members apoptosis, it is possible that therapeutic strategies that
disrupt Stat3 signaling will not only prevent malignanthas been identified in many tumor types, overexpression
of these proteins alone may not be sufficient for full progression but also may confer sensitivity to some
chemotherapeutic drugs. Thus, agents that selectivelyoncogenic transformation. However, the extended life-
span of myeloma tumor cells by constitutive activation block Stat3 signaling could be used in combination with
conventional chemotherapy for more effective antitumorof Stat3 may facilitate disease progression by allowing
the accumulation of mutations and chromosomal trans- therapy. These findings identify Stat3 as a potential tar-
get for therapeutic intervention in MM and other humanlocations, such as in ras and c-myc (Hallek et al., 1998).
Our results are also compatible with a role for Ras- cancers with activated Stat3 signaling.
The high incidence of Stat3 activation in human tumordependent, MAP kinase signaling pathways in regulat-
ing proliferation of MM tumor cells (Ogata et al., 1997). cells of diverse origins (Migone et al., 1995; Gouilleux-
Gruart et al., 1996; Weber-Nordt et al., 1996; Zhang etSimilarly, we do not exclude the possibility that Stat3-
independent signaling pathways, such as the JNK/SAPK al., 1996; Chai et al., 1997; Garcia et al., 1997; Takemoto
et al., 1997; Garcia and Jove, 1998) suggests an impor-pathway, may participate in regulating survival of my-
eloma cells (Chauhan et al., 1997). Our findings provide tant role for aberrant activation of Stat3 signaling in
regulating fundamental cellular processes associatedfurther support for a multistep model of transformation
during malignant progression in MM (Hallek et al., 1998). with malignant transformation. Consistent with an indis-
pensable function during development (Takeda et al.,Results presented here also have significant implica-
tions for treatment of human cancers with activated 1997), Stat3 signaling has been implicated in regulation
of apoptosis, differentiation, and cell proliferation (Fu-Stat3 signaling. Elevated Bcl-xL expression has been
indicated as a mechanism of resistance to some chemo- kada et al., 1996; Ihara et al., 1997; Bromberg et al.,
1998; Turkson et al., 1998). Therefore, activated Stat3therapeutic drugs that utilize cellular apoptosis path-
ways to eliminate tumor cells (Simonian et al., 1997; signaling may contribute to oncogenesis by perturbing
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MBL) or 100 ng/ml Fas ligand (Alexis) for 18±24 hr. Apoptosis wasany one of these biological processes. Although we
measured by staining with Annexin V-FITC (Clontech) and flow cy-show that Stat3 regulates apoptosis in myeloma cells,
tometry analysis. Fas-specific death is calculated as (percentwe do not exclude a role for Stat3 in controlling cell
Annexin V±positive cells in the CH-11 treated population) 2 (percent
proliferation in other tumor cells. It is possible that Stat3 Annexin V±positive cells in the IgM control population). Programmed
regulates genes in addition to bcl-x that may also con- cell death in cells transfected with the bicistronic green fluorescent
protein vectors (pIRES-EGFP or pIRES-Stat3b) was analyzed aftertribute to oncogenesis, such as those involved in cell
staining with Annexin V-PE (Pharmingen) by two-color flow cytome-cycle control. Moreover, while IL-6 is associated with a
try analysis. Apoptotic morphology of DAPI-stained nuclei andwide variety of human tumors in addition to MM, there
green/red fluorescence was confirmed by fluorescence microscopy.are likely to be additional mechanisms for activation of
Stat3 signaling in different tumor types. For example, Western Blot Analysis
the Src and EGF receptor tyrosine kinases, both of which Cells were lysed in a buffer composed of 50 mM Tris-Cl (pH 7.4), 5
induce Stat3, are frequently activated in breast carci- mM EDTA, 150 mM NaCl, and 0.5% Triton-X 100 containing 1 mg/
ml leupeptin and aprotinin and 1 mM PMSF. Protein content of thenoma and other tumor cells (Garcia et al., 1997; Sartor
cell lysates was quantified by the Bradford assay (Bio-Rad), and 15et al., 1997; Garcia and Jove, 1998). Our findings provide
mg total protein was dissolved in Laemmli SDS-PAGE sample bufferevidence that constitutively activated Stat3 in human
prior to separation by 10% SDS-PAGE. Proteins were transferred
tumor cells contributes to malignant progression by to PVDF membrane and Western blot analysis was performed by
conferring a survival advantage through suppression of standard techniques with ECL detection (Amersham). The Bcl-2
apoptosis. antibody, clone 124 (Dako), was used at a 1:2000 dilution. The Bcl-xL
antibody, clone S-18 (Santa Cruz Biotechnology), was used at a
1:500 dilution. Blots were quantified by densitometry and expressionExperimental Procedures
levels were normalized to b-actin (Sigma).
Cells and Inhibitors
RNA Isolation and RT±PCR AnalysisU266 and RPMI 8226 cell lines were originally obtained from ATCC
Total RNA was isolated by lysis in guanidine isothiocyanate followedand maintained in RPMI 1640 medium supplemented with 10% fetal
by centrifugation through a cesium chloride gradient. cDNA wascalf serum (FCS). For detection of STATs in primary bone marrow
prepared from 200 ng of total RNA in a 40 ml reaction with AMV-RT(BM) cells, BM aspirates were diluted 1:2 in phosphate-buffered
(Boehringer-Mannheim). Specific gene amplification was performedsaline (PBS) and mononuclear cells were separated by the standard
on 5 ml of the cDNA reaction with the following primers: bcl-2, 59-Ficoll-Hypaque (Pharmacia LKB Biotechnology) sedimentation pro-
CGACGACTTCTCCCGCCGCTACCGC-39 and 59-CCGCATGCTGGGcedure. Mononuclear cells were washed twice with PBS, and nuclear
GCCGTACAGTTCC-39, which corresponds to bases 1761±1785;extracts were prepared as described below. For inhibitor studies,
bcl-x, 59-CGGGCATTCAGTGACCTGAC-39 and 59-TCAGGAACCAGa minimum of 107 U266 cells were treated with 1 mg/ml Sant7 as
CGGTTGAAG-39, which amplifies a 340 bp amplicon of bcl-xL or apreviously described (Sporeno et al., 1996) or with 50 mM AG490
151 bp amplicon of bcl-xS; and histone 3.3, 59-CCACTGAACTTCTG(Meydan et al., 1996). NIH 3T3 cells overexpressing the human EGF
ATTCGC-39 and 59-GCGTGCTAGCTGGATGTCTT-39. Ten microlitersreceptor have been described (Garcia et al., 1997).
of PCR products were electrophoresed on a 5% acrylamide gel and
quantified by phosphorimaging using ImageQuant software (Molec-Nuclear Extracts and EMSA
ular Dynamics).Nuclear extracts were prepared as previously described (Yu et al.,
1995; Garcia et al., 1997). Briefly, nuclei were isolated and extracted
Construction of Plasmidsin hypertonic buffer (20 mM HEPES [pH 7.9], 420 mM NaCl, 1 mM
The murine bcl-x promoter reporter constructs were derived fromEDTA, 1 mM EGTA, 20% glycerol, 20 mM NaF, 1 mM Na3VO4, 1 mM
a 3.2 kb genomic fragment containing the 59 region of the bcl-xNa2P4O7, 1 mM DTT, 0.5 mM PMSF, 0.1 mM aprotinin, 1 mM leupeptin,
gene upstream of the ATG translational start codon and have beenand 1 mM antipain). Extracts were normalized for total protein, and
described in detail (Grillot et al., 1997). To construct the pGL2-2±6 mg protein was incubated with the 32P-labeled high-affinity SIE
mST1 reporter, three bases were mutated in the Stat1-binding motifprobe (59-AGCTTCATTTCCCGTAAATCCCTA-39) derived from the
(normal, TTCGGAGAA; mutant, TGAGGATAA) at position 2315 toc-fos gene promoter, as described (Yu et al., 1995; Garcia et al.,
2307 (Grillot et al., 1997) in the 600 bp fragment of the mouse bcl-x1997). Protein±DNA complexes were resolved on 5% nondenaturing
promoter. The equivalent site in the human promoter was mutatedpolyacrylamide gels and analyzed by autoradiography. Controls
previously (Fujio et al., 1997). The pMvSrc vector encoding v-Srcwere performed using rabbit polyclonal antibodies specific for Stat1,
protein has been described (Turkson et al., 1998). To constructStat3, or Stat5 proteins (Santa Cruz Biotechnology). The anti-Stat3
pIRES-Stat3b, the human Stat3b gene (Caldenhoven et al., 1996)and anti-Stat5 antibodies supershift DNA-binding complexes,
was excised from plasmid pSG5hStat3b (kindly provided by E. Cal-whereas the anti-Stat1 antibodies block complex formation (Yu et
denhoven and R. de Groot) by XhoI digestion, made blunt-endedal., 1995; Garcia et al., 1997). For competition assays, nuclear ex-
with Klenow fragment of DNA polymerase, and subcloned into thetracts containing equal amounts of total protein were incubated with
EcoRV site of pIRES-EGFP vector (Clontech). The structure of100-fold molar excess of unlabeled SIE oligonucleotide or unlabeled
pIRES-Stat3b was confirmed by restriction mapping, DNA sequenc-irrelevant oligonucleotide, which contains the c-fos intragenic regu-
ing, and functional analyses in transient transfections.latory element (FIRE, 59-GTCCCCCGGCCGGGGAGGCGCT-39).
Flow Cytometry and Apoptosis Assays Transfections and Luciferase Assays
Transfections of NIH 3T3 were performed by the calcium-phosphateFor surface detection of the Fas receptor, 106 cells were suspended
in 100 ml PBS with 2.5 mg/ml mouse IgM (Sigma) and 100 mg UB2 method as previously described (Turkson et al., 1998). A total of 20
mg of DNA was added to cells, including 4 mg of the indicatedantibody (MBL) or IgG1 isotype control serum (Dako). Following 30
min incubation at room temperature, cells were washed with PBS luciferase reporter construct, 200 ng b-galactosidase expression
vector, and 4±8 mg each of pMvSrc or pIRES-Stat3b. Cells wereand incubated in the dark for 30 min with goat anti-mouse Ig-FITC.
Fluorescence was measured on a FACScan flow cytometer and incubated for 48 hr, lysed, and cytosolic extracts prepared as de-
scribed (Turkson et al., 1998). The cytosolic fractions were usedanalyzed using CellQuest software (Becton Dickinson). For cell cycle
analysis, 106 cells were fixed in ice-cold ethanol for a minimum of for luciferase assays (Promega) and analyzed with a luminometer.
Samples were normalized to b-galactosidase activity by colorimetric2 hr, washed with PBS, and stained with 5 mg/ml propidium iodide
(PI) and 50 mg/ml RNase A at 378C for 30 min prior to analysis by assay at A570 as an internal control for transfection efficiency.
Transfections of the U266 myeloma cell line were performed byflow cytometry. Sensitivity to Fas-mediated apoptosis was deter-
mined by exposing cells to 500 ng/ml agonistic antibody (CH-11, adding DNA to 300 ml RPMI 1640 media and mixing with 30 ml
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TransIT-LT1 (PanVera). A total of 25 mg of DNA was added in 10 ml Fujio, Y., Kunisada, K., Hirota, H., Yamauchi-Takihara, K., and Kishi-
moto, T. (1997). Signals through gp130 upregulate bcl-x gene ex-serum-free media, including 8 mg of the indicated luciferase reporter
pression via STAT1-binding cis-element in cardiac myocytes. J. Clin.construct, 2 mg of b-galactosidase vector, and 8 mg of pIRES-Stat3b
Invest. 99, 2898±2905.or pIRES-EGFP. Cells were incubated 3 hr and fresh media was
added to give a final concentration of 10% FCS. Cytosolic extracts Fukada, T., Hibi, M., Yamanaka, Y., Takahashi-Tezuka, M., Fujitani,
were prepared 48 hr posttransfection, and luciferase activities were Y., Yamaguchi, T., Nakajima, K., and Hirano, T. (1996). Two signals
normalized to b-galactosidase activity in all samples as described are necessary for cell proliferation induced by a cytokine receptor
above. gp130: involvement of STAT3 in anti-apoptosis. Immunity 5,
449±460.
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